Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 08, 2020 | May 11, 2020 |
| GLAUKOS CorpGKOS · Entity 3510 | Director | June 03, 2021 | June 07, 2021 |
| LENSAR, Inc.LNSR · Entity 6733 | Director | June 03, 2026 | June 05, 2026 |
| Oyster Point Pharma, Inc.OYST · Entity 15903 | Director | January 05, 2022 | January 07, 2022 |
| RxSight, Inc.RXST · Entity 1226 | Director | June 17, 2026 | June 18, 2026 |
| Tarsus Pharmaceuticals, Inc.TARS · Entity 1836 | Director | September 15, 2026 | September 17, 2026 |
| Vivani Medical, Inc.EYES · Entity 6636 | Director | June 04, 2019 | June 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 08, 2020 · Filed May 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,349 |
Ending reported balance
After 2020-05-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-05-08 · Grant · Acquired 1,101 · Balance 11,004 F1: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Row 2 · 2020-05-08 · Grant · Acquired 345 · Balance 11,349 F2: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. |
| Common StockSEC Table I · non-derivative | IndirectLink Family Enterprise, LP | 4,722 |
Reported balance
Holding disclosure · report date 2020-05-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,722 |
| Common StockSEC Table I · non-derivative | IndirectLink Family Trust | 6,050 |
Reported balance
Holding disclosure · report date 2020-05-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 6,050 |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.
F2: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.
GLAUKOS Corp
Report date June 03, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,821 |
Reported balance
After 2021-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 2,382 · Balance 17,821 F1: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2: Includes 2,382 restricted stock units that have not yet vested or been delivered to the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 40,479 |
Reported balance
Holding disclosure · report date 2021-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 40,479 F3: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.
F2: Includes 2,382 restricted stock units that have not yet vested or been delivered to the Reporting Person.
F3: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.
LENSAR, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 568,062 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 568,062 F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.
Oyster Point Pharma, Inc.
Report date January 05, 2022 · Filed January 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 33,480 |
Reported balance
After 2022-01-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-01-05 · Other · Acquired 6,438 · Balance 33,480 F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV. F2: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,074 |
Reported balance
After 2022-01-05 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-01-05 · Other · Acquired 401 · Balance 2,074 F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration. F4: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy LLC | 27,942 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,942 F5: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC. |
| Common StockSEC Table I · non-derivative | Direct | 10,066 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 10,066 |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,465 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,465 F6: Shares held by Versant Side Fund IV following its distribution to the Reporting Person reported herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 414,607 |
Reported balance
Holding disclosure · report date 2022-01-05 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 414,607 F7: Shares held by Capital IV following its distribution to the Reporting Person herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Capital IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Capital IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV.
F2: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.
F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration.
F4: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust.
F5: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC.
F6: Shares held by Versant Side Fund IV following its distribution to the Reporting Person reported herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F7: Shares held by Capital IV following its distribution to the Reporting Person herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Capital IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Capital IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
RxSight, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,892 |
Reported balance
After 2026-06-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 74,892 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock. F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 21,248 |
Reported balance
Holding disclosure · report date 2026-06-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 21,248 F3: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.
F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.
F3: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein.
Tarsus Pharmaceuticals, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,487 |
Ending reported balance
After 2026-09-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 201 · Balance 106,987 F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. Row 2 · 2026-09-15 · Sale · Disposed 11,675 · Balance 95,312 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-09-15 · Sale · Disposed 759 · Balance 94,553 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-09-15 · Sale · Disposed 66 · Balance 94,487 F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 605 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 201 · Balance 605 F5: Each RSU represents a contingent right to receive one share of the Company's common stock. F6: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: Each RSU represents a contingent right to receive one share of the Company's common stock.
F6: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.
Vivani Medical, Inc.
Report date June 04, 2019 · Filed June 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-06-04 | Direct | 56,685 |
Reported balance
After 2019-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-04 · Grant · Acquired 56,685 · Balance 56,685 F1: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting. F2: Awarded as compensation for serving on the Board of Directors and its committees. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting.
F2: Awarded as compensation for serving on the Board of Directors and its committees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2021 Filed May 14, 2021 20:42 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock | 10,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-032758 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 20,604 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV. F2 · ownership.nature: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. Read SEC document |
| March 26, 2021 Filed Mar 31, 2021 01:45 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock | 631 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023694 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 631 F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration. F4 · ownership.nature: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust. Read SEC document |
| March 26, 2021 Filed Mar 31, 2021 01:45 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock | 10,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023694 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 10,302 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV. F2 · ownership.nature: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP. Read SEC document |
| December 10, 2020 Filed Dec 15, 2020 01:45 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock | 27,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063362 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 27,942 F3 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Flying L Partners VII, LLC in connection with the pro-rata distribution described in footnote (1) herein. F4 · ownership.nature: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC. Read SEC document |
| December 10, 2020 Filed Dec 15, 2020 01:45 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | OtherCommon Stock | 955,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-063362 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Oyster Point Pharma I, LLC, without consideration, to its members. F2 · ownership.nature: Shares originally held by Oyster Point Pharma I, LLC. The Reporting Person may have been deemed to have beneficially owned the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, LLC. Read SEC document |
| December 07, 2020 Filed Dec 11, 2020 01:53 UTC | LENSAR, Inc. LNSR · Entity 6733 | GrantCommon Stock | 80,157 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-033401 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,694 F1 · shares: Represents restricted stock awarded to the Reporting Person on December 7, 2020 in connection with an amendment on the same date to the restricted stock awarded to him on July 22, 2020 to amend and extend the vesting schedule applicable to such award (the "Original Award"). In order to comply with tax laws and to recognize the Reporting Person's agreement to an extension of the overall vesting schedule of the Original Award, the Reporting Person was issued the restricted stock award, which represents 20% of the total number of shares subject to the Original Award. The restricted stock award will vest on the same amended vesting schedule applicable to the Original Award, which amended vesting schedule provides for vesting in quarterly installments over the approximately three-year period following the amendment date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · derivative · entry 9 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Granted June 2, 2016 pursuant to the Issuer's 2015 Omnibus Incentive Compensation Plan. Vests in full on the one-year anniversary of the grant date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.00 | $0.00 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · derivative · entry 8 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-07-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Granted on July 23, 2015 pursuant to the Issuer's 2015 Stock Plan. Vests annually over a three-year period such that it is vested in full on the three-year anniversary of the grant date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · derivative · entry 7 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-07-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Granted July 10, 2014 pursuant to the Issuer's 2011 Stock Plan. Vests annually over a three-year period such that it is vested in full on the three-year anniversary of the grant date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 600 | $68.72 | $41,231.82 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 5 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,439 F3 · price: This transaction was executed in multiple trades at prices ranging from $68.68 to $68.785. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 49,400 | $67.96 | $3,357,090.62 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,039 F2 · price: This transaction was executed in multiple trades at prices ranging from $67.68 to $68.675. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 15,000 | $24.69 | $370,350.00 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 25,000 | $32.00 | $800,000.00 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:39 UTC | GLAUKOS Corp GKOS · Entity 3510 | Exercise / conversionCommon Stock | 10,000 | $7.28 | $72,750.00 |
DisclosureSEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:57 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionSeries B Preferred Stock · Derivative | 1,112,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055422 · doc4.xml · derivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flying L Investments XI, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,112,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly held by Flying L Investments XI, LLC. The Reporting Person is the manager of Flying L Investments XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 23:57 UTC | Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 | ConversionCommon Stock | 1,112,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055422 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Flying L Investments XI, LLC Disclosed balance after: 1,112,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date. F2 · ownership.nature: The shares are held directly held by Flying L Investments XI, LLC. The Reporting Person is the manager of Flying L Investments XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 01:15 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | GrantCommon Stock | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035748 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,600 F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date. Read SEC document |
| June 03, 2020 Filed Jun 6, 2020 01:21 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019057 · form4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,439 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 345 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007365 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,349 F2 · shares: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2020 Filed May 11, 2020 18:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007365 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,004 F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:31 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-000905 · a4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,539 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,766 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionSeries B Convertible Preferred Stock · Derivative | 955,392 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · derivative · entry 7 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 955,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F5 · ownership.nature: Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,654,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · derivative · entry 6 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 1,654,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Venture Capital IV, L.P. ("Versant IV"). F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionSeries A Convertible Preferred Stock · Derivative | 10,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · derivative · entry 5 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 10,420 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV"). F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionCommon Stock, par value $0.001 per share | 955,392 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 955,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F5 · ownership.nature: Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | PurchaseCommon Stock, par value $0.001 per share | 27,500 | $16.00 | $440,000.00 |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 2,002,298 F3 · ownership.nature: Shares held by Versant Venture Capital IV, L.P. ("Versant IV"). F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionCommon Stock, par value $0.001 per share | 1,654,359 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 1,974,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: Shares held by Versant Venture Capital IV, L.P. ("Versant IV"). F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 04, 2019 Filed Nov 4, 2019 22:51 UTC | Oyster Point Pharma, Inc. OYST · Entity 15903 | ConversionCommon Stock, par value $0.001 per share | 10,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 12,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV"). F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| August 21, 2019 Filed Aug 21, 2019 21:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,650 | $222.02 | $366,327.89 |
DisclosureSEC source: 0001225208-19-011800 · doc4.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Link Family Enterprise, LP Disclosed balance after: 4,722 Read SEC document |
| August 21, 2019 Filed Aug 21, 2019 21:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,914 | $221.56 | $1,531,861.69 |
DisclosureSEC source: 0001225208-19-011800 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,903 F1 · price: This transaction was executed in multiple trades at prices ranging from $221.17 to $222.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 21:59 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 1,650 | $222.98 | $367,918.98 |
DisclosureSEC source: 0001225208-19-011800 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,817 Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 20:15 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon-Qualified Stock Option(right to buy) · Derivative | 56,685 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-19-034727 · doc4.xml · derivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,685 Underlying: Common Stock · 56,685 shares Expires 2029-06-04 F1 · derivative.exercise_date: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting. F2 · derivative.underlying_shares: Awarded as compensation for serving on the Board of Directors and its committees. Read SEC document |
| May 30, 2019 Filed Jun 1, 2019 00:07 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-033246 · a4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,426 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,793 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 414 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007860 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,467 F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020. Read SEC document |
| May 09, 2019 Filed May 13, 2019 22:35 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-007860 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,053 F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board. Read SEC document |
| January 02, 2019 Filed Jan 16, 2019 21:28 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 2,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-000314 · primarydocument.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,773 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 6,773 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 01:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 10,950 | $149.88 | $1,641,203.52 |
DisclosureSEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Link Family Trust Disclosed balance after: 6,050 F3 · kind: This transaction was executed in multiple trades at prices ranging from $149.68 to $150.39. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 01:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,628 | $150.06 | $394,363.99 |
DisclosureSEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Link Family Enterprise, LP Disclosed balance after: 6,372 F1 · kind: This transaction was executed in multiple trades at prices ranging from $150.03 to $150.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes shares that were previously aggregated with other shares reported as held indirectly. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 23:28 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 1,300 | $58.18 | $75,634.00 |
DisclosureSEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 4 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 40,479 F4 · price: This transaction was executed in multiple trades at prices ranging from $58.10 to $58.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| November 15, 2018 Filed Nov 15, 2018 23:28 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 25,725 | $57.37 | $1,475,843.25 |
DisclosureSEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 41,779 F3 · price: This transaction was executed in multiple trades at prices ranging from $57.00 to $57.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| November 14, 2018 Filed Nov 15, 2018 23:28 UTC | GLAUKOS Corp GKOS · Entity 3510 | GiftCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 67,504 F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 23:28 UTC | GLAUKOS Corp GKOS · Entity 3510 | SaleCommon Stock | 14,475 | $58.01 | $839,694.75 |
DisclosureSEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 76,004 F1 · price: This transaction was executed in multiple trades at prices ranging from $58.00 to $58.045. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 31, 2018 Filed Nov 21, 2018 01:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 3 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Link Family Trust Disclosed balance after: 17,000 F2 · balance_after: Includes shares that were previously aggregated with other shares reported as held indirectly. Read SEC document |
| August 31, 2018 Filed Nov 21, 2018 01:24 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,730 Read SEC document |
| June 02, 2018 Filed Jun 6, 2018 01:00 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantNon Qualified Stock Option (right to buy) · Derivative | 25,970 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001437749-18-011317 · rdgdoc.xml · derivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,970 Underlying: Common Stock · 25,970 shares Expires 2028-06-02 F1 · derivative.underlying_shares: Awarded as compensation for serving on the Board of Directors and its committees. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 01:00 UTC | Vivani Medical, Inc. EYES · Entity 6636 | GrantCommon Stock | 34,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-011317 · rdgdoc.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,186 F1 · shares: Awarded as compensation for serving on the Board of Directors and its committees. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 20:33 UTC | GLAUKOS Corp GKOS · Entity 3510 | GrantCommon Stock | 4,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002759 · primarydocument.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,633 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 4,633 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document |
| May 18, 2018 Filed May 22, 2018 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 479 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009753 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,730 F2 · shares: This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. Read SEC document |
| May 18, 2018 Filed May 22, 2018 23:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,655 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-009753 · doc4.xml · nonDerivative · entry 1 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,251 F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 23:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,400 | $122.08 | $1,025,502.24 |
DisclosureSEC source: 0001225208-18-002799 · doc4.xml · nonDerivative · entry 2 LINK WILLIAM J PHD · CIK 0001228684 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · * Disclosed balance after: 16,000 F3 · price: This transaction was executed in multiple trades at prices ranging from $121.47 to $122.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Held by the Link Family Trust, dated May 31, 1990, and the Link Family Enterprise, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.